bmi for glp 1 GLP-1 Use Has More Than Quadrupled Since 2021 as Obesity Rates Continue to Show Signs of Decline Pharmacological interventions for obesity in

GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple AgonistsMechanism of Action and Emerging Therapeutic Landscape in #MASLD Bruno Ramos Molinas Post GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple AgonistsMechanism of Action and Emerging Therapeutic Landscape in #MASLD

Regular followup and dose adjustments help optimize safety

11 Current evidence related to the effects of GLP-1 RAs on HF outcomes remains limited

GLP-1R agonists increase signaling through ActRIIA/B via myostatin and activin A [174]

2025;15(1):e089477

FDA has given these companies a facility-dependent grace period of 60 to 90 days to stop selling compounded GLP-1 drugs before the agency takes enforcement action, aiming to avoid unnecessary disruptions in patient care